Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000306649 | SCV000342395 | uncertain significance | not provided | 2016-07-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001855205 | SCV002169729 | uncertain significance | GM3 synthase deficiency | 2021-08-30 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine with tyrosine at codon 181 of the ST3GAL5 protein (p.His181Tyr). The histidine residue is highly conserved and there is a moderate physicochemical difference between histidine and tyrosine. This variant is present in population databases (rs750698842, ExAC 0.003%). This variant has not been reported in the literature in individuals affected with ST3GAL5-related conditions. ClinVar contains an entry for this variant (Variation ID: 288317). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C15"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |